Clinical trials: Histological Type of Neoplasm
Neuroendocrine Tumors
Entinostat Neuroendocrine (NE) Tumor
This is an open-label, single arm, multi-center Phase II trial of entinostat given as a 5 mg oral dose every week (days 1, 8, 15, and 22 of a 4-week cycle) in patients with relapsed or refractory abdominal neuroendocrine (NE)…
- Trial name
- NCT03211988
- Testing
- Entinostat
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Antonio Fojo
Acute Lymphocytic Leukemia
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side…
- Trial name
- NCT03104491
- Testing
- Inotuzumab Ozogamicin
- Where
- 7 sites in United States
- Volunteers
- 44 people
- Sponsor
- Leland Metheny
Leukemia
Efficacy of Seated Exercise on Functional Capacity and Quality of Life in Patients With Leukemia During Chemotherapy Cycles
This study aims to evaluate the efficacy of seated exercise on functional capacity and quality of life in patients with leukemia during chemotherapy cycles Participants will receive efficacy of seated exercise on functional…
- Trial name
- NCT07740174
- Testing
- Seated exercise
- Volunteers
- 30 people
- Sponsor
- Suez University
Renal Cell Carcinoma
Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
This is a pilot, single-center, single-arm study where 20 patients with metastatic or unresectable clear cell renal cell carcinoma will receive same sequential treatment strategy (Cabozantinib for 12 weeks, then proceed with…
- Trial name
- NCT05188118
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Meningiomas
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
This research study is studying targeted immunotherapies as a possible treatment for recurrent meningioma. The names of the study interventions involved in this study are nivolumab and ipilimumab.
- Trial name
- NCT02648997
- Testing
- Nivolumab - 240 mg, Ipilimumab - 1 mg/kg, Nivolumab - 480 mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Bladder Cancer
Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC
This study assesses the effect of sequential radiation and durvalumab immunotherapy given as treatment prior to surgery with radical cystectomy for bladder cancer.
- Trial name
- RADIANT (NCT04543110)
- Testing
- Durvalumab, Immune Modulating Radiation
- Where
- 4 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Ottawa Hospital Research Institute
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed…
- Trial name
- NCT04925713
- Testing
- IFx-Hu2.0
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- TuHURA Biosciences, Inc.
Nasopharyngeal Carcinoma, Metastasis
SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma
Primary metastatic NPC patients received chemotherapy± immunotherapy, radiation for primary tumors and SBRT for metastatic lesions.
- Conditions
- Nasopharyngeal Carcinoma, Metastasis, Stereotactic Body Radiation Therapy
- Trial name
- NCT04351282
- Testing
- SBRT
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fudan University
Multiple Myeloma, Plasma Cell Dyscrasia
Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)
To assess the efficacy and toxicity of plerixafor (AMD 3100) together with granulocyte-colony stimulating factor (G-CSF) for stem cell mobilisation, in patients with myeloma or lymphoma requiring high dose chemotherapy with stem…
- Conditions
- Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoma, Lymphoproliferative Disorders
- Trial name
- PHANTASTIC (NCT01186224)
- Testing
- Plerixafor and G-CSF
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Liverpool
Leukemia, Leukemia, Myeloid
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
This is a phase 1b/2, open-label, single arm study to evaluate if enasidenib is safe and effective in improving anemia and decreasing transfusion needs in subjects diagnosed with lower risk myelodysplastic syndrome (MDS) or…
- Conditions
- Leukemia, Leukemia, Myeloid, Monocytic Leukemia
- Trial name
- NCT05282459
- Testing
- Enasidenib mesylat dose escalation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Tian Yi Zhang
Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease
Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19
The COVID-19 epidemic (Coronavirus Disease 2019) which is currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2).
- Trial name
- COVID19_LLC-MW (NCT04391946)
- Testing
- Data registry
- Where
- 22 sites in France
- Volunteers
- 162 people
- Sponsor
- French Innovative Leukemia Organisation
Multiple Myeloma, Multiple Myeloma in Relapse
Ixazomib + Pomalidomide + Dexamethasone In MM
This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.
- Trial name
- NCT04094961
- Testing
- Ixazomib, Pomalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Omar Nadeem, MD
Metastatic Melanoma
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
A phase 2, open-label randomized, multicenter trial to compare CC-486 in combination with Abraxane administered weekly with respect to overall survival, objective tumor response rate and Progression-Free Survival (PFS) in…
- Trial name
- NCT01933061
- Testing
- Abraxane
- Sponsor
- Celgene Corporation
Malignant Glioma, Glioblastoma Multiforme
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00024570
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- INSYS Therapeutics Inc
Osteosarcoma, Ewing Sarcoma
Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma
Osteosarcoma and Ewing sarcoma treatment has not changed in the last 30 years. For other types of cancer the epidemiologic and prognostic correlations between dietary behavior, lifestyle and metabolic alterations (i.e.obesity…
- Trial name
- Metabol-Sarc (NCT04735289)
- Testing
- EPIC-COS Food Frequency Questionnaire diet Evaluation, Metabolome, Microbiota, Lymphocytes subpopulations
- Where
- 7 sites in Italy
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- Istituto Ortopedico Rizzoli
Pseudomyxoma Peritonei, Colorectal Cancer
HIPEC Using High Intra-abdominal Pressure
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising therapy for peritoneal carcinomatosis (PC) of various origins.
- Trial name
- HIPEC-IAP (NCT02949791)
- Testing
- Cytoreductive surgery, Low Intra abdominal pressure HIPEC, High Intra abdominal pressure HIPEC
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Anaplastic Oligoastrocytoma, Glioblastoma
A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme
This study was to explore the effectiveness and safety of early TMZ chemotherapy between surgery and chemoradiotherapy plus the standard concomitant radiochemotherapy regimen.
- Trial name
- NCT05600491
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
Solid Tumors, Lymphoma
Phase I Study of CS-7017 and Bexarotene
This study is for patients with advanced solid tumors. The purpose of this study is to test the safety and effectiveness of a new combination of drugs, CS-7017 and Bexarotene in patients with advanced cancer.
- Conditions
- Solid Tumors, Lymphoma, Multiple Myeloma
- Trial name
- NCT01504490
- Testing
- CS-7017 and Bexarotene
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Georgetown University
Marginal Zone Lymphoma
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past.
- Trial name
- NCT04212013
- Testing
- Ibrutinib, Rituximab
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as ifosfamide and vinorelbine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00006760
- Testing
- filgrastim, ifosfamide, vinorelbine tartrate
- Where
- 114 sites in United States, Australia and 1 more
- Volunteers
- 66 people
- Sponsor
- Children's Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.